Pharmacokinetic, biodistribution, safety and efficacy studies of borophenylalanine (BPA) in BNCT in hepatocellular carcinoma cells and tumor-bearing mouse model
Authors:
Open Access
- 9 August 2025
- journal article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 29212
Abstract
Boron neutron capture therapy (BNCT), using boronophenylalanine (BPA) as the main boron carrier, is a dual-targeted particle radiotherapy at the cellular level. Although BPA shows clinical promise in liver cancer, there is relatively little basic research on its effect on hepatocellular carcinoma. Therefore, we systematically evaluated the uptake, safety, pharmacokinetics, and therapeutic efficacy of BPA. Boron uptake in hepatocellular carcinoma cells (Hepa1-6, HepG2) was quantified by ICP-AES, revealing concentration- and time-dependent accumulation (plateau at 6 h), while CCK-8 assays indicated significant cytotoxicity at 24 h. Pharmacokinetic studies in Sprague-Dawley (SD) rats showed rapid boron distribution (peak at 25 ± 5.8 min) with a blood clearance half-life of 74.71 ± 52.22 min. In tumor-bearing mouse models, BPA achieved tumor-specific targeting, with tumor-to-normal tissue (T/N) and tumor-to-blood (T/B) ratios exceeding 2 and 4, respectively, at 2 h post-injection, followed by rapid systemic clearance. Cell viability significantly decreased after BPA-BNCT irradiation, and the tumor growth inhibition rate in mice reached 77%. BPA did not produce tissue damage in vivo, and there were no abnormalities in blood counts or liver or kidney function in vivo after irradiation. These findings suggest that BPA can be selectively enriched in hepatocellular tumors with good pharmacokinetics and therapeutic efficacy, supporting its clinical application in BNCT of hepatocellular carcinoma.Keywords
All Related Versions
This publication has 26 references indexed in Scilit:
- Boron Neutron Capture Therapy in the Treatment of Recurrent Laryngeal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- Clinical potential of boron neutron capture therapy for locally recurrent inoperable previously irradiated head and neck cancerApplied Radiation and Isotopes, 2015
- Experimental Studies of Boronophenylalanine (10BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma TreatmentInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Boramino acid as a marker for amino acid transportersScience Advances, 2015
- The application of allometric scaling principles to predict pharmacokinetic parameters across speciesExpert Opinion on Drug Metabolism & Toxicology, 2014
- BNCT for advanced or recurrent head and neck cancerApplied Radiation and Isotopes, 2014
- First Attempt of Boron Neutron Capture Therapy (BNCT) for Hepatocellular CarcinomaJapanese Journal of Clinical Oncology, 2007
- Feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Boron biodistribution in Beagles after intravenous infusion of 4-dihydroxyborylphenylalanine–fructose complexApplied Radiation and Isotopes, 2004
- Evaluation of 4-borono-2-18F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model.2004